Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232829 · ClinicalTrials.gov registry record · Phase 2
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
A Phase 2 study of Stage IV Pancreatic Cancer and Adenocarcinoma of the Pancreas, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT01232829 is a Phase 2 study of Stage IV Pancreatic Cancer and Adenocarcinoma of the Pancreas that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01232829, a Phase 2 study of Stage IV Pancreatic Cancer and Adenocarcinoma of the Pancreas, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG gamma-secretase/Notch signalling pathway inhibitor RO4929097
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Anschutz Cancer Pavilion - Aurora
- University of Colorado - Denver
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232829
The ClinicalTrials.gov registry entry for NCT01232829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (77% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which gamma-secretase/Notch signalling pathway inhibitor RO4929097 is the first listed.
NCT01232829 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT01232829 about?
NCT01232829 is a clinical study titled "Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer". This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.
What is the current status of trial NCT01232829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2010-10. Estimated completion is 2014-05.
What conditions does trial NCT01232829 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer, Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer.
What interventions are being tested in trial NCT01232829?
The interventions under investigation include: gamma-secretase/Notch signalling pathway inhibitor RO4929097 (DRUG).
Who is sponsoring clinical trial NCT01232829?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01232829 being conducted?
This trial has 3 study locations across Colorado, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.